Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 28/05/2024 BST			5-day change	1st Jan Change
33.09 ^USD	+0.33%		-8.31%	+53.76%

05-15	Spyre Therapeutics, Inc. Announces Board Changes	CI
05-13	Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating	MT

Aeglea Biotherapeutics, Inc. Announces Resignation of Leslie Sloan as Chief Operating Officer

January 06, 2023 at 12:31 pm

Effective January 5, 2023, Leslie Sloan will no longer serve as Chief Operating Officer of Aeglea BioTherapeutics, Inc. Dr. Sloan's departure is not related to any legal, compliance or other matters of the Company.

Latest news about Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. Announces Board Changes	05-15	CI
Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating	05-13	MT
Spyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target	05-02	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	04-19	MT
Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares	04-19	MT
Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating	03-26	MT
Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding	03-17	CI
North American Morning Briefing : Powell Still in -2-	03-07	DJ
North American Morning Briefing : Stock Futures -2-	03-04	DJ
Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12	03-01	MT
Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Spyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Spyre Therapeutics, Inc. Announces Board Changes	02-05	CI
Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors	12-26	CI
BTIG Initiates Spyre Therapeutics With Buy Rating, Price Target is $32	12-20	MT
Stifel Adjusts Price Target on Spyre Therapeutics to $27 From $23, Keeps Buy Rating	12-18	MT
Jefferies Initiates Spyre Therapeutics at Buy Rating With $31 Price Target	12-11	MT
Spyre Therapeutics Agrees to Sell Shares in Private Placement for Expected Gross Proceeds of About $180 Million	12-08	MT
Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors	12-06	CI
Spyre Therapeutics, Inc.(NasdaqCM:SYRE) added to NASDAQ Composite Index	11-29	CI
Aeglea BioTherapeutics, Inc. will Change its Ticker to SYRE from AGLE	11-28	CI
Aeglea BioTherapeutics, Inc. will Change its Name to Spyre Therapeutics, Inc	11-28	CI
Aeglea BioTherapeutics Changes Name to Spyre Therapeutics; CEO Appointed	11-27	MT
Aeglea BioTherapeutics, Inc. Appoints Cameron Turtle as Chief Executive Officer	11-27	CI

Chart Spyre Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Spyre Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

33.09 USD

Average target price

45 USD

Spread / Average Target

+35.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SPYRE THERAPEUTICS, INC.	+53.76%	1.33B
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	118B
REGENERON PHARMACEUTICALS, INC.	+10.80%	106B
BIONTECH SE	-10.84%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.11%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.03B
SAREPTA THERAPEUTICS, INC.	+17.53%	11.67B

Bio Therapeutic Drugs